ADC Review | Journal of Antibody-Drug Conjugates is an Open Access hybrid, peer reviewed publication. The publication includes a Social Media (peer-to-peer) shell with a controlled but freely accessible Open Access peer review journal.
Operating as usual
Robust development and manufacturing solutions for your ADCs.
Robust development and manufacturing solutions for your ADCs Robust Development and Manufacturing Solutions for your ADCs Greetings! Antibody Drug Conjugates (ADCs) are one of the fastest growing ther
Your Personal Invitation | ADC Symposium | December 2, 2020 or December 3, 2020
Your Personal Invitation | ADC Symposium |December 2, 2020 or December 3, 2020
Your Personal Invitation
ADC Symposium
December 2, 2020, or December 3, 2020
Oncology Expert 5 Things you May have Missed from the ESMO 2020 Virtual Congress
Headlines from Onco'Zine The Onco'Zine Newsletter - Tuesday, September 25, 2020 | Volume 2 Edition 4 Things You May Have Missed... ESMO 2020 Virtual Congress ESMO 2020 Virtual Congress Tisotumab Vedot
5 Things you May have Missed from the ESMO 2020 Virtual Congress
Headlines from Onco'Zine The Onco'Zine Newsletter - Tuesday, September 25, 2020 | Volume 2 Edition 4 Things You May Have Missed... ESMO 2020 Virtual Congress ESMO 2020 Virtual Congress Tisotumab Vedot
The Onco'Zine Newsletter: 5 Things you May have Missed Last Month. Click to read: https://conta.cc/3h76gBw
Click on the link below to sign up to receive our newsletter (Onco'Zine and ADC Review | Journal of Antibody-drug Conjugates):
https://conta.cc/32c3yq8
With 9 FDA-approved and commercially available ADCs, and many more in clinical development, It's important to stay up to date with news about Antibody-drug Conjugates. Sign up for the ADC Review newsletter: https://conta.cc/3gMvdT4
Are you interested in the latest news about the advances in the development of Antibody-drug Conjugates (ADCs) in the treatment of patients with cancer or hematological malignancies? Are you interested in learning about the development of ADCs beyond cancer?
If so, sign up for the ADC Review | Journal of Antibody-drug Conjugates Newsletter at
https://lnkd.in/eyR5Y3b
The Newsletter is developed by the Publishers of ADC Review | Journal of Antibody-drug Conjugates and Onco'Zine.
Sign Up Here!
Stay up-to-date with R&D and regulatory updates of Antibody-drug Conjugates (ADC) in HemOnc. Click on the link to sign up for our Newsletter!
https://adc.expert/newsletterandwebinars
@ASCO @AACR @CPhIww #oncoogy #hematology @myESMO @AAPSonline @AAPSComms #pharma @world_ADC
The promise of Immunological memory. Bolt Biotherapeutics’ Immune-Stimulating Antibody Conjugate (ISAC) selectively target tumors for destruction by the immune system.
Piramal Pharma Solutions and Bolt Biotherapeutics Sign Production Agreement » ADC Review
Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase II Trial Collaboration » ADC Review
Daiichi Sankyo and Gustave Roussy Sign Multi-year and Multi-study Adaptive Phase II Trial Collaboration » ADC Review
Sign Up for the ADC Review | Journal of Antibody-drug Conjugates Newsletter.
Stay on top of the latest developments involving Antibody-drug Conjugates.
Enjoy a selection of the most-read articles published in ADC Review | Journal of Antibody-drug Conjugates, handpicked by our editorial team. When you sign up for our mailing list, you'll also receive our overview of scheduled educational webinar presentations.
https://adc.expert/newsletterandwebinars
#ADC #antibodydrugconjugate #drugdevelopment #webinars #medicaleducation #cancer #cancertreatment #beyondcancer
Sign Up Here!
In an episode of The Onco'Zine Brief, Peter Hofland talks with Thorsten Sperber, Global Head Medical Affairs at Immunomedics.
Hofland and Sperber talk about sacituzumab govitecan, a novel antibody-drug conjugate. At the time of this interview, the drug was not yet approved, but in the weeks following the interview, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan (Trodelvy™) for the treatment of adult patients with metastatic triple-negative breast cancer
https://lnkd.in/gw7RBkq
https://www.spreaker.com/user/7078249/tob-sacituzumab-govitecan-mtnbc-001
Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial
https://www.adcreview.com/news/loncastuximab-tesirine-demonstrates-an-high-response-rates-in-pivotal-phase-ii-single-agent-trial/
AACR Foundation American Association of Pharmaceutical Scientists (AAPS) CPhI
Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial » ADC Review
Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritis
https://www.adcreview.com/news/beyond-oncology-abbv-3373-shows-improvement-in-disease-activity-in-phase-iia-study-in-rheumatoid-arthritis/
#rheumatoid #arthritis #antibodydrugconjugate #research #immunotherapy #clinicaltrial #ADC
CPhI American Association of Pharmaceutical Scientists (AAPS) AbbVie Careers Genmab
Beyond Oncology: ABBV-3373 Shows Improvement in Disease Activity in Phase IIa Study in Rheumatoid Arthritis » ADC Review
Abbvie and Genmab Sign $ 3.9 Billion Agreement to develop next-gen bispecific antibody programs, epcoritamab, DuoHexaBody®-CD37, and DuoBody-CD3x5T4.
https://www.adcreview.com/business-economics/abbvie-and-genmab-sign-u-s-3-9-billion-development-agreement/
AACR Foundation American Association of Pharmaceutical Scientists (AAPS) CPhI
AbbVie and Genmab Sign U.S. $ 3.9 Billion Development Agreement » ADC Review
![[WEBINAR] Spaces are filling up fast for our webinar on Tuesday, May 26th at 11:00 am PDT /2:00 pm EDT.Reserve your spot...](https://scontent.fymy1-1.fna.fbcdn.net/v/t1.0-9/s720x720/99131832_2938104616273889_5012175423673466880_n.png?_nc_cat=108&ccb=2&_nc_sid=8024bb&_nc_ohc=aaTQ3uQjGHgAX82Lz6X&_nc_ht=scontent.fymy1-1.fna&_nc_tp=30&oh=d42aa087adc3c356968d27f387fef9a1&oe=602CF22E)
[WEBINAR] Spaces are filling up fast for our webinar on Tuesday, May 26th at 11:00 am PDT /2:00 pm EDT.
Reserve your spot today and join us for a WEBINAR discussing TRPH-222 Preclinical Development and Interim Phase I Data: Enhancing Clinical Safety and Overcoming ADC Manufacturing Challenges with SMARTag® Technology
Click on the link to register:
http://www.adc.expert/trph222-webinar
Join us for a WEBINAR discussing TRPH-222 Preclinical Development and Interim Phase I Data: Enhancing Clinical Safety and Overcoming ADC Manufacturing Challenges with SMARTag® Technology
Tuesday, May 26, 2020 at 11.00 am (PDT) / 2.00 pm (EDT)
Click on the link to register: adc.expert/trph222-webinar
Interim Results of Phase I Clinical Trial of TRPH-222 in R/R non-Hodgkin’s Lymphoma Confirms Safety with Early Signs of Efficacy » ADC Review
Interim Results of Phase I Clinical Trial of TRPH-222 in R/R non-Hodgkin’s Lymphoma Confirms Safety with Early Signs of Efficacy » ADC Review
Netherlands-based Synthon Biopharmaceuticals, a biopharmaceutical research, and development company creating innovative precision medicines including the anti-HER2 investigational antibody-drug conjugate (ADC) [vic-]trastuzumab duocarmazine, previously known as SYD985 for the treatment breast cancer, has been relaunched as Byondis.
» ADC Review Synthon Biopharmaceuticals, developing trastuzumab duocarmazine (SYD985,) relaunched as Byondis.
The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease.
FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer » ADC Review
With the FDA’s decision earlier this week to approve sacituzumab govitecan (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease, the number of approved and commercially available ADC has grown to eight, making ADCs a powerful class of therapeutic agents in oncology and hematology.
To stay up to date, join the LinkedIn group of ADC Review | Journal of Antibody-drug Conjugates at https://lnkd.in/g3agyJA
500 million+ members | Manage your professional identity. Build and engage with your professional network. Access knowledge, insights and opportunities.
Have you seen our latest news?
Important announcement: Changing the Way We Meet is Now More Important than Ever.
American Society of Clinical Oncology
Don’t miss out on the lowest registration rates and access to the most sought-after hotels.
American Society of Clinical Oncology
Get ready for #ASCO20! Learn about the latest advances and issues concerning cancer care. This year’s new interactive style includes shorter presentations and session formats designed to enhance engagement.
Stand Up To Cancer
We’re live from the SU2C Summit discussing an overview for cancer research and what we can look forward to in the future. Featuring: John D. Carpten, PhD and Roderic I. Pettigrew, MD, PhD.
CPhI
Join us at the only event in North America with the entire pharma supply chain under one roof! Network, source, learn and innovate May 5-7, 2020 at the Pennsylvania Convention Center, Philadelphia.
COPE: Promoting integrity in scholarly research and its publication
A study in BMC Medicine found that the use of an online CONSORT-based Peer Review Tool (COBPeer) by trained early career researchers compared to usual peer review processes resulted in better detection of inadequate reporting in RCTS and suggests that using two-step peer review process could improve the quality of reporting. http://ow.ly/erPU50xAWGb
CPhI
Acting as a business facilitator, CPhI South East Asia 2020 attracts pharmaceutical suppliers, buyers and distributors for 3 days of sourcing, networking and market updates, while onsite industry associations give businesses like yours hands on advice around how to enter the market and register products.
The number of antibody-drug conjugates entering the clinic is rapidly growing. While this may be the case of HER2-targeting ADCs, growth has especially been noted the development of ADC-targeting B7-H3 and TROP2.
https://www.adcreview.com/editorial/rapid-advances-in-the-development-of-novel-adcs-targeting-b7-h3-and-trop2/
Rapid Advances in the Development of Novel ADCs Targeting B7-H3 and TROP2 » ADC Review
Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics » ADC Review
Randall Schatzman, Ph.D. to Lead Growth of Immune-Stimulating Antibody Conjugates at Bolt Biotherapeutics » ADC Review
Attending #WorldADC in SanDiego, CA this week? Download @ADCBIO 's new brochure designed to give you an overview of the company's Development, Manufacturing and Analytical Services + expertise. Click: https://adc.expert/2MtaxC0
ADC Directory, A Guide to the World of Antibody-drug Conjugates
Design of Experiments (DoEs) are a specific application of statistical techniques to enable rapid and robust development. Those techniques can be directed towards factor screening or process robustness depending on the specific needs of the project phase. Often these experiments result in a stronger process understanding, while requiring less time and fewer material resources. Watch the Presentation On Demand.
https://adc.expert/NovasepDOE
Be the first to know and let us send you an email when ADC Review / Journal of Antibody-drug Conjugates posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to ADC Review / Journal of Antibody-drug Conjugates:
Opening of CPhI NA ...
ADC Review / Journal of Antibody-drug Conjugates is a new, hybrid, open access, peer reviewed journal designed to bring together the entire span of researchers and scientists from academia, the life sciences and pharmaceutical industry involved in the growing field of Antibody-drug Conjugates (ADCs).
In addition to original research and review articles, the Journal provides its audience with timely news, information and resources from around the world in all areas of Antibody-drug Conjugates development.
ADC Review / Journal of Antibody-drug Conjugates is published by InPress Media Group.
The full publication is available at http://www.adcreview.com.
For more information about underwriting, sponsorship and advertising, in ADC Review | Journal of Antibody-drug Conjugates welcome opportunities to discuss underwriting, sponsorship and advertisement options. To find out more, call Shaun Mehr at +1 949.923.1660 or email: [email protected]
These opportunities could enable you to:
Breathing Light Wellness Coaching
120 South Main Street Suite D, KernersvilleTONYA-The insurance lady • US Health Advisor
3200 Troup Hwy, TylerRosebud Healthcare and Training
3024 Westfork Drive Suite B, Baton RougeEssentially You with Shelly McCauley
Lakewood